GIE AXA

Their core work

GIE AXA is the research and innovation arm of AXA Group, one of Europe's largest insurance and financial services companies. In H2020, they contributed industry expertise in data analytics, risk assessment, and healthcare — areas directly tied to their insurance business. Their participation focuses on applying machine learning and big data to real-world problems like population health management, oncology outcomes, and seismic risk — all domains where insurers need better predictive models.

What they specialise in

How they've shifted over time

Their earliest involvement (2017) was in fundamental machine learning research — geometric algorithms, clustering, and unstructured data analysis via the LAMBDA project. By 2018, they shifted toward applied domains: healthcare big data (BigMedilytics) and natural hazard risk (URBASIS). This progression from foundational ML to sector-specific applications reflects a maturing data science capability being deployed to insurance-relevant problems.

Moving from general ML research toward domain-specific predictive analytics in health and natural catastrophe risk — areas with direct commercial value for insurance.

How they like to work

GIE AXA never coordinates — they join as a participant or third-party partner, contributing industry use cases and data rather than leading research agendas. With 53 unique partners across 15 countries in just 3 projects, they operate in large consortia where they serve as an end-user voice. This suggests they are valuable as a real-world validation partner who can provide data access and commercial perspective.

Despite only 3 projects, they have collaborated with 53 partners across 15 countries — a consequence of joining large-scale EU consortia. Their network is broad but not deep, reflecting their role as an industry end-user rather than a research hub.

What sets them apart

As a major insurer participating in EU research, GIE AXA offers something rare: access to real-world data at scale and a clear commercial pathway for research outputs. For researchers needing an industry partner who can validate ML models against actual insurance, health, or risk data, AXA brings both the datasets and the business case. Few other H2020 participants combine financial services scale with genuine R&D engagement.

Highlights from their portfolio

• BigMedilytics
  Largest EU big data for healthcare project (Innovation Action), where AXA received their highest single funding (EUR 87,500) for population health and oncology analytics.
• LAMBDA
  Marie Skłodowska-Curie research network on massive data analysis — unusual for an insurance company to participate in fundamental ML training programs.